echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > For the treatment of non-small cell lung cancer, the results of the first Phase 3 controlled trial of KRAS inhibitors were released

    For the treatment of non-small cell lung cancer, the results of the first Phase 3 controlled trial of KRAS inhibitors were released

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎ WuXi AppTec content team editor

    Today, at the annual meeting of the European Society of Oncology (ESMO), amgen's KRAS G12C inhibitor Lumakras (sotorasib) released




    KRAS gene mutations are one of the most common oncogene mutations in cancer patients, and it was once a well-known "incurable" target



    CodeBreaK 200 is a randomized, active-controlled, phase 3 clinical trial designed to compare the efficacy and safety




    Trial results showed that in these patients who had received multiple pre-treatments, Lumakas reduced the risk of disease progression or death by 34% compared with standard chemotherapy (HR: 0.



    "The overall evidence for this study supports Lumakras as an important targeted therapy option for patients with non-small cell lung cancer carrying KRAS G12C mutations and highlights the urgent need



    Krass-targeted drug development has developed rapidly in recent years, and in addition to Amgen's Lumakras, Mirati's Adagrasib is being reviewed by the U.




    ▲If you have any business needs, please long press to scan the QR code above, or


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.